{"drugs":["Albiglutide","Tanzeum"],"mono":{"0":{"id":"930934-s-0","title":"Generic Names","mono":"Albiglutide"},"1":{"id":"930934-s-1","title":"Dosing and Indications","sub":[{"id":"930934-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Type 2 diabetes mellitus:<\/b> initial, 30 mg SUBQ once weekly; may increase to 50 mg SUBQ once weekly<\/li><li><b>Type 2 diabetes mellitus:<\/b> missed dose, administer as soon as possible if within 3 days and resume weekly dosing; if more than 3 days have elapsed, wait until next scheduled dose<\/li><\/ul>"},{"id":"930934-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in patients younger than 18 years "},{"id":"930934-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no adjustments required<\/li><li><b>hepatic impairment:<\/b> no adjustments required <\/li><li><b>concomitant use with an insulin secretagogue (eg, sulfonylurea) or insulin:<\/b> consider reducing the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia<\/li><\/ul>"},{"id":"930934-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Type 2 diabetes mellitus<br\/>"}]},"2":{"id":"930934-s-2","title":"Black Box Warning","mono":"<b>Subcutaneous (Powder for Solution)<\/b><br\/>Thyroid C-cell tumors have been observed in animal studies with glucagon-like peptide-1 (GLP-1) receptor agonists at clinically relevant exposures. It is unknown if albiglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Albiglutide is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2. Counsel patients about the potential risk of MTC with albiglutide and the symptoms of thyroid tumors. Routine monitoring of serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection of MTC.<br\/>"},"3":{"id":"930934-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930934-s-3-9","title":"Contraindications","mono":"<ul><li>Hypersensitivity to albiglutide or any product component<\/li><li>Personal or family history of medullary thyroid carcinoma<\/li><li>Multiple endocrine neoplasia syndrome type 2<\/li><\/ul>"},{"id":"930934-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Possible increased risk for thyroid C-cell tumors<\/li><li>Endocrine and Metabolic:<\/li><li>-- Increased risk of hypoglycemia with concomitant use of insulin or insulin secretagogues (eg, sulfonylureas); consider reducing dose of insulin or sulfonylurea when initiating albiglutide<\/li><li>Gastrointestinal:<\/li><li>-- Acute pancreatitis has been reported; monitoring recommended; discontinue if suspected and do not restart if confirmed<\/li><li>-- History of pancreatitis; consider alternative therapy<\/li><li>-- Preexisting severe gastrointestinal disease; use not recommended<\/li><li>Immunologic:<\/li><li>-- Serious hypersensitivity reactions, with pruritus, rash, and dyspnea, have been reported; discontinue if hypersensitivity occurs<\/li><li>Renal:<\/li><li>-- Acute renal failure and worsening of chronic renal failure have been reported, with some events occurring in patients without underlying renal disease; caution advised when initiating or escalating doses in patients with renal impairment<\/li><\/ul>"},{"id":"930934-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930934-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930934-s-4","title":"Drug Interactions","sub":{"1":{"id":"930934-s-4-14","title":"Major","mono":"<ul><li>Amisulpride (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Lanreotide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lurasidone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},"2":{"id":"930934-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Esmolol (probable)<\/li><li>Furazolidone (probable)<\/li><li>Insulin (probable)<\/li><li>Insulin Aspart, Recombinant (probable)<\/li><li>Insulin Bovine (probable)<\/li><li>Insulin Degludec (probable)<\/li><li>Insulin Detemir (probable)<\/li><li>Insulin Glulisine (probable)<\/li><li>Insulin Lispro, Recombinant (probable)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Labetalol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Linezolid (probable)<\/li><li>Methylene Blue (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moclobemide (probable)<\/li><li>Nadolol (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nialamide (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Phenelzine (probable)<\/li><li>Pindolol (probable)<\/li><li>Practolol (probable)<\/li><li>Procarbazine (probable)<\/li><li>Propranolol (probable)<\/li><li>Rasagiline (probable)<\/li><li>Selegiline (probable)<\/li><li>Simvastatin (probable)<\/li><li>Sotalol (probable)<\/li><li>Timolol (probable)<\/li><li>Tranylcypromine (probable)<\/li><\/ul>"}}},"5":{"id":"930934-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (10.5% to 18%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (13.1%), Nausea (11.1%)<\/li><li><b>Respiratory:<\/b>Upper respiratory infection (14.2%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypoglycemia, Severe (combination therapy, 0.4% to 1%), Medullary thyroid carcinoma<\/li><li><b>Gastrointestinal:<\/b>Appendicitis (0.3%), Pancreatitis, Acute (0.3%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (0.9%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Renal:<\/b>Renal failure<\/li><li><b>Respiratory:<\/b>Pneumonia (1.8%)<\/li><\/ul>"},"6":{"id":"930934-s-6","title":"Drug Name Info","sub":{"0":{"id":"930934-s-6-17","title":"US Trade Names","mono":"Tanzeum<br\/>"},"2":{"id":"930934-s-6-19","title":"Class","mono":"<ul><li>Antidiabetic<\/li><li>Glucagon-Like Peptide-1 Receptor Agonist<\/li><\/ul>"},"3":{"id":"930934-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930934-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930934-s-7","title":"Mechanism Of Action","mono":"Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist which acts to augment glucose-dependent insulin secretion, thereby lowering fasting glucose and reducing postprandial glucose excursions. Albiglutide also delays gastric emptying.<br\/>"},"8":{"id":"930934-s-8","title":"Pharmacokinetics","sub":[{"id":"930934-s-8-23","title":"Absorption","mono":"Tmax, subQ: 3 to 5 days<br\/>"},{"id":"930934-s-8-24","title":"Distribution","mono":"Vd, subQ: 11 L <br\/>"},{"id":"930934-s-8-25","title":"Metabolism","mono":"primarily in vascular endothelium via catabolism by ubiquitous proteolytic enzymes <br\/>"},{"id":"930934-s-8-26","title":"Excretion","mono":"Total body clearance: 67 mL\/hr <br\/>"},{"id":"930934-s-8-27","title":"Elimination Half Life","mono":"approximately 5 days<br\/>"}]},"9":{"id":"930934-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>Do not administer IM or IV.<br\/><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>Reconstitute lyophilized powder with diluent by holding pen body with clear cartridge pointing up so the number [1] appears in the window; twist cartridge in the direction of the arrow until the number [2] appears and a \"click\" is heard.<\/li><li>Reconstitution instructions for patients:<\/li><li>-- Slowly rock pen side to side 5 times to mix; do not shake to avoid foaming.<\/li><li>-- Wait 15 minutes for the 30-mg pen and 30 minutes for the 50-mg pen to ensure complete reconstitution; the reconstituted solution will be yellow; use within 8 hours.<\/li><li>-- Following the wait time, again slowly and gently rock the pen side to side 5 times to remix.<\/li><li>Alternative reconstitution for more rapid dissolution (healthcare professional use only):<\/li><li>-- Reconstitute lyophilized powder with diluent by holding pen body with clear cartridge pointing up so the number [1] appears in window; twist cartridge in the direction of the arrow until the number [2] appears and a \"click\" is heard.<\/li><li>-- Gently swirl pen for 1 minute; inspect and continue to swirl until all powder is dissolved.<\/li><li>-- Complete dissolution for 30-mg pen usually occurs within 2 minutes (may require up to 5 minutes); for the 50-mg pen, dissolution usually occurs within 7 minutes (may require up to 10 minutes).<\/li><li>-- Confirm the solution is clear and free of particles; normally a small amount of foam may appear on top of solution after reconstitution.<\/li><li>Follow steps below to attach needle, prime pen injector, and administer injection:<\/li><li>-- To attach needle, hold pen upright and push needle straight down onto clear cartridge until it clicks; gently tap clear cartridge to bring large bubbles to the top; remove air bubbles by slowly twisting until [3] appears in window; injection button will automatically release from bottom of pen; use immediately after needle is attached and primed as product can clog needle.<\/li><li>-- Administer any time of day, independent of meals.<\/li><li>-- Inject SUBQ in abdomen, thigh, or upper arm by pressing injection button; hold button until a \"click\" is heard, then hold for 5 additional seconds to deliver full dose.<\/li><li>-- Administer once a week on the same day each week; may change day of weekly administration as long as the last dose was administered 4 or more days prior<\/li><li>-- Do not mix with insulin; do not administer adjacent to insulin.<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930934-s-10","title":"Monitoring","mono":"<ul><li>achieving glycemic control, including meeting HbA1c goal is indicative of efficacy<\/li><li>HbA1c; twice yearly in patients who are meeting treatment goals; every 3 months in patients whose therapy has changed and\/or who are not meeting glycemic goals; more frequently as clinically warranted<\/li><li>blood glucose (self-monitoring); as needed to assist in meeting goals of therapy<\/li><li>elevated serum calcitonin levels, thyroid nodules, and\/or abnormalities of thyroid ultrasound warrant a referral to an endocrinologist<\/li><li>renal function; in patients with renal impairment presenting with severe gastrointestinal adverse reactions<\/li><li>signs or symptoms of pancreatitis<\/li><\/ul>"},"11":{"id":"930934-s-11","title":"How Supplied","mono":"<b>Tanzeum<\/b><br\/>Subcutaneous Powder for Solution: 30 MG, 50 MG<br\/>"},"13":{"id":"930934-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient to discontinue drug use at least one month before a planned pregnancy.<\/li><li>Side effects may include diarrhea, nausea, upper respiratory tract infection, cough, sinusitis, influenza, injection site reactions, or back or joint pain.<\/li><li>Advise patient to report symptoms of thyroid tumors (eg, lump in the neck, hoarseness, dysphagia, or dyspnea).<\/li><li>Counsel patient to discontinue drug and contact a physician if symptoms of hypersensitivity or severe abdominal pain occurs.<\/li><li>Instruct patient to report signs\/symptoms of pancreatitis (ie, severe abdominal pain that may radiate to the back and may (or may not) be accompanied by vomiting).<\/li><li>Counsel patient to report signs\/symptoms of hypoglycemia<\/li><li>Advise patient on proper use, storage, and disposal of pen.<\/li><li>Instruct patient to administer once a week on the same day each week.<\/li><li>Advise patient to administer any time of the day, independent of meals.<\/li><li>Instruct patient to administer a missed dose as soon as possible if within 3 days and resume weekly dosing on usual day. If more than 3 days have elapsed, advise patient to wait until next scheduled dose.<\/li><\/ul>"}}}